Refractory Candidozyma (Candida) auris-associated central nervous system infection in a postoperative neurosurgical patient. (PubMed, ASM Case Rep) - May 7, 2026 - "Combination antifungal therapy with liposomal amphotericin B, flucytosine, and micafungin, later supplemented with posaconazole, was initiated but was complicated by significant toxicities requiring dose adjustments and stepwise discontinuation...Given persistent recovery of the organism, the clinical team initiated the US Food and Drug Administration Single Patient IND process to obtain fosmanogepix, an investigational antifungal agent, although the request was ultimately discontinued as the patient clinically stabilized. She was discharged on long-term oral voriconazole for antifungal suppression because of persistent CSF isolation of C. auris, multidrug resistance, and limited CNS penetration of previously administered antifungals. This case highlights diagnostic uncertainty, therapeutic challenges, and antifungal decision-making complexities following isolation of C. auris from CSF."
Journal • Infectious Disease • Musculoskeletal Pain • Oncology • Pain
|
|
Khadija Thomas; Noor Zaidan; Ping Ren; Yuan Chao Xue
|